POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c

Detalhes bibliográficos
Autor(a) principal: DANIEL CAMILO FONSECA CAVALCANTI
Data de Publicação: 2024
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Repositório Institucional da UFMS
Texto Completo: https://repositorio.ufms.br/handle/123456789/9067
Resumo: Chagas disease is caused by the protozoan Trypanosoma cruzi. It is classified as a neglected tropical disease and is endemic in Latin America, where up to 7 million people are believed to be infected. The available treatments for this disease are not very effective in the chronic phase and also have adverse effects. The process of discovering new drugs is long and expensive, so drug repositioning strategies are gaining ground as they can reduce costs and time to market. The aim of this study was to evaluate the activity of two drugs, previously selected in silico, on metacyclic trypomastigotes of T. cruzi Dm28c. Cytotoxicity tests were performed with the drugs oxiconazole (OXI) and lansoprazole (LZP) against Vero cells and metacyclic trypomastigote forms obtained in vitro, under chemically defined conditions, with the aim of determining the concentration capable of inhibiting 50% of parasite viability. Subsequently, tests were performed to evaluate the influence of the drugs on the process of metacyclogenesis in vitro. Using the CC50 (50% cytotoxic concentration) and IC50 (50% inhibitory concentration) data, the SI (selectivity index) was calculated. OXI showed a cytotoxic effect with a CC50 of 45.11 μM, in contrast to LZP which showed no cytotoxicity. OXI had an effect on trypomastigote forms with an IC50 of 279.6 μM and an IS of 0.16, while LZP had an IS of 2.46 and less activity against the parasite. Both drugs had an effect on the differentiation process, where intermediate forms were more abundant than metacyclic trypomastigotes, indicating that the drugs affected the process from the onset of differentiation, preventing or delaying its completion. Thus, both drugs had an effect during metacyclogenesis, but only OXI acted against the metacyclic trypomastigote forms.
id UFMS_254324169ab26a58cac7881bbe2d6f3a
oai_identifier_str oai:repositorio.ufms.br:123456789/9067
network_acronym_str UFMS
network_name_str Repositório Institucional da UFMS
repository_id_str 2124
spelling 2024-07-22T12:46:56Z2024-07-22T12:46:56Z2024https://repositorio.ufms.br/handle/123456789/9067Chagas disease is caused by the protozoan Trypanosoma cruzi. It is classified as a neglected tropical disease and is endemic in Latin America, where up to 7 million people are believed to be infected. The available treatments for this disease are not very effective in the chronic phase and also have adverse effects. The process of discovering new drugs is long and expensive, so drug repositioning strategies are gaining ground as they can reduce costs and time to market. The aim of this study was to evaluate the activity of two drugs, previously selected in silico, on metacyclic trypomastigotes of T. cruzi Dm28c. Cytotoxicity tests were performed with the drugs oxiconazole (OXI) and lansoprazole (LZP) against Vero cells and metacyclic trypomastigote forms obtained in vitro, under chemically defined conditions, with the aim of determining the concentration capable of inhibiting 50% of parasite viability. Subsequently, tests were performed to evaluate the influence of the drugs on the process of metacyclogenesis in vitro. Using the CC50 (50% cytotoxic concentration) and IC50 (50% inhibitory concentration) data, the SI (selectivity index) was calculated. OXI showed a cytotoxic effect with a CC50 of 45.11 μM, in contrast to LZP which showed no cytotoxicity. OXI had an effect on trypomastigote forms with an IC50 of 279.6 μM and an IS of 0.16, while LZP had an IS of 2.46 and less activity against the parasite. Both drugs had an effect on the differentiation process, where intermediate forms were more abundant than metacyclic trypomastigotes, indicating that the drugs affected the process from the onset of differentiation, preventing or delaying its completion. Thus, both drugs had an effect during metacyclogenesis, but only OXI acted against the metacyclic trypomastigote forms.A doença de Chagas é causada pelo protozoário Trypanosoma cruzi. Classificada como uma Doença Tropical Negligenciada e endêmica da América Latina, acredita-se que até 7 milhões de pessoas estejam infectadas. Os tratamentos disponíveis para essa doença são pouco eficientes na fase crônica, além de apresentarem efeitos adversos. O processo de descoberta de novos fármacos é longo e de alto custo, sendo assim estratégias de reposicionamento de fármacos vem ganhando destaque, pois possibilita a redução de custos e período até sua disponibilização para uso. O objetivo deste trabalho foi avaliar a atividade de dois fármacos, selecionados previamente in silico, sobre formas tripomastigotas metacíclicas de T. cruzi Dm28c. Foram realizados ensaios de citotoxicidade com os fármacos Oxiconazol (OXI) e Lansoprazol (LZP) frente às células Vero e em formas tripomastigotas metacíclicas, obtidas in vitro, sob condições quimicamente definidas com o objetivo de determinar a concentração capaz de inibir 50% da viabilidade dos parasitos. Posteriormente, foram realizados ensaios para avaliar a influência dos fármacos sobre o processo de metaciclogênese in vitro. Com os dados obtidos de CC50 (concentração citotóxica de 50%) e CI50 (concentração inibitória de 50%) foi calculado o IS (Índice de Seletividade). O OXI apresentou efeito citotóxico com CC50 de 45,11 μM, ao contrário do LZP que não apresentou citotoxicidade. O OXI teve efeito sobre formas tripomastigotas, com CI50 de 279,6 μM de 0,16, já o LZP teve um IS de 2,46 e com menor atividade contra o parasito. Ambos os fármacos foram ativos sobre o processo de diferenciação, onde formas intermediárias estiveram mais presentes que as tripomastigotas metacíclicas, revelando que desde o período de deflagração da diferenciação os fármacos afetaram o processo, impedindo ou retardando a finalização do mesmo. Sendo assim, os dois fármacos apresentaram efeito durante a metaciclogênese, contudo, apenas o OXI apresentou atividade contra as formas tripomastigotas metacíclicas.Fundação Universidade Federal de Mato Grosso do SulUFMSBrasilDoença de ChagasIn silicoKinetoplastidaMetaciclogêneseReposicionamento de fármacosPOTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28cinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisAlda Maria Teixeira FerreiraDANIEL CAMILO FONSECA CAVALCANTIinfo:eu-repo/semantics/openAccessporreponame:Repositório Institucional da UFMSinstname:Universidade Federal de Mato Grosso do Sul (UFMS)instacron:UFMSORIGINALDissertação_Daniel_Camilo.pdfDissertação_Daniel_Camilo.pdfapplication/pdf1123726https://repositorio.ufms.br/bitstream/123456789/9067/-1/Disserta%c3%a7%c3%a3o_Daniel_Camilo.pdfd2f144b81c25df6f4db9c477da095b86MD5-1123456789/90672024-07-22 08:46:57.686oai:repositorio.ufms.br:123456789/9067Repositório InstitucionalPUBhttps://repositorio.ufms.br/oai/requestri.prograd@ufms.bropendoar:21242024-07-22T12:46:57Repositório Institucional da UFMS - Universidade Federal de Mato Grosso do Sul (UFMS)false
dc.title.pt_BR.fl_str_mv POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c
title POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c
spellingShingle POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c
DANIEL CAMILO FONSECA CAVALCANTI
Doença de Chagas
In silico
Kinetoplastida
Metaciclogênese
Reposicionamento de fármacos
title_short POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c
title_full POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c
title_fullStr POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c
title_full_unstemmed POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c
title_sort POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c
author DANIEL CAMILO FONSECA CAVALCANTI
author_facet DANIEL CAMILO FONSECA CAVALCANTI
author_role author
dc.contributor.advisor1.fl_str_mv Alda Maria Teixeira Ferreira
dc.contributor.author.fl_str_mv DANIEL CAMILO FONSECA CAVALCANTI
contributor_str_mv Alda Maria Teixeira Ferreira
dc.subject.por.fl_str_mv Doença de Chagas
In silico
Kinetoplastida
Metaciclogênese
Reposicionamento de fármacos
topic Doença de Chagas
In silico
Kinetoplastida
Metaciclogênese
Reposicionamento de fármacos
description Chagas disease is caused by the protozoan Trypanosoma cruzi. It is classified as a neglected tropical disease and is endemic in Latin America, where up to 7 million people are believed to be infected. The available treatments for this disease are not very effective in the chronic phase and also have adverse effects. The process of discovering new drugs is long and expensive, so drug repositioning strategies are gaining ground as they can reduce costs and time to market. The aim of this study was to evaluate the activity of two drugs, previously selected in silico, on metacyclic trypomastigotes of T. cruzi Dm28c. Cytotoxicity tests were performed with the drugs oxiconazole (OXI) and lansoprazole (LZP) against Vero cells and metacyclic trypomastigote forms obtained in vitro, under chemically defined conditions, with the aim of determining the concentration capable of inhibiting 50% of parasite viability. Subsequently, tests were performed to evaluate the influence of the drugs on the process of metacyclogenesis in vitro. Using the CC50 (50% cytotoxic concentration) and IC50 (50% inhibitory concentration) data, the SI (selectivity index) was calculated. OXI showed a cytotoxic effect with a CC50 of 45.11 μM, in contrast to LZP which showed no cytotoxicity. OXI had an effect on trypomastigote forms with an IC50 of 279.6 μM and an IS of 0.16, while LZP had an IS of 2.46 and less activity against the parasite. Both drugs had an effect on the differentiation process, where intermediate forms were more abundant than metacyclic trypomastigotes, indicating that the drugs affected the process from the onset of differentiation, preventing or delaying its completion. Thus, both drugs had an effect during metacyclogenesis, but only OXI acted against the metacyclic trypomastigote forms.
publishDate 2024
dc.date.accessioned.fl_str_mv 2024-07-22T12:46:56Z
dc.date.available.fl_str_mv 2024-07-22T12:46:56Z
dc.date.issued.fl_str_mv 2024
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://repositorio.ufms.br/handle/123456789/9067
url https://repositorio.ufms.br/handle/123456789/9067
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Fundação Universidade Federal de Mato Grosso do Sul
dc.publisher.initials.fl_str_mv UFMS
dc.publisher.country.fl_str_mv Brasil
publisher.none.fl_str_mv Fundação Universidade Federal de Mato Grosso do Sul
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFMS
instname:Universidade Federal de Mato Grosso do Sul (UFMS)
instacron:UFMS
instname_str Universidade Federal de Mato Grosso do Sul (UFMS)
instacron_str UFMS
institution UFMS
reponame_str Repositório Institucional da UFMS
collection Repositório Institucional da UFMS
bitstream.url.fl_str_mv https://repositorio.ufms.br/bitstream/123456789/9067/-1/Disserta%c3%a7%c3%a3o_Daniel_Camilo.pdf
bitstream.checksum.fl_str_mv d2f144b81c25df6f4db9c477da095b86
bitstream.checksumAlgorithm.fl_str_mv MD5
repository.name.fl_str_mv Repositório Institucional da UFMS - Universidade Federal de Mato Grosso do Sul (UFMS)
repository.mail.fl_str_mv ri.prograd@ufms.br
_version_ 1815448050494078976